Hoffmann-la Roche Inc.

Boehringer Mannheim Gmbh

Roche Glycart Ag

Gsf-forschungszentrum Fur Umwelt Und Gesundheit, Gmbh

F. Hoffmann-la Roche Ag

Manfred Kubbies

Ulrike Reiff

Georg Fertig

Anja Limberg

Frank Herting

Matthias Koerner

Michael Weidner

Ulrich Tibes

Frederick Arthur Brookfield

Olaf Mundigl

Edward Andrew Boyd

Wolfgang Von Der Saal

Georg Tiefenthaler

Jonathan Gridley

Raymond Lau

Timothy Woodcock

Christian Klein

Ekkehard Moessner

Tilman Schlothauer

Petra Rueger

Michael Jarsch

Monika Baehner

Thomas Von Hirschheydt

Axel Schmidt

Stefan Jenewein

Bernhard Goller

Rudolf Gompper

Stefan Koch

Thorsten Hoevel

Petra Meissner

Peter D&ouml;rmer

Nora Torres-Nagel

Andrea Challand

Bernhard Virnekas

Herein is reported a cell analytical technology based on a three-dimensional spheroid/aggregate co-culture assay, wherein the spheroid or aggregate is formed of tumor and natural killer cells. This method is useful for the in vitro functional analysis of antibodies in single and high-throughput format.

3D ADCC NK FACS assay

An antibody binding to human EPO-R, characterized in specifically binding pY461, pY430 or p465 is useful for the determination of activated EPO receptor.

Antibodies against human EPO receptor

The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.

Antibody Fc variants

Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer. 

Hydroxamates, their manufacture and use as pharmaceutical agents

Mono-acylated o-phenylendiamines derivatives of formula A: which are useful for the treatment of diseases mediated by the inhibition of histone deacetylase, such as cancer.

Mono-acylated o-phenylendiamines derivatives

Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer. 

Thiophene hydroxamic acid derivatives and their use as HDAC inhibitors

Thiophene derivatives, their manufacture and use as pharmaceutical agents

The present invention relates to compounds of formula I wherein R, Rand Rare defined herein, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.

Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents

Mono-acylated o-phenylendiamines derivatives of formula I wherein X and R are as described herein, have been found useful for the treatment of diseases mediated by the inhibition of histone deacetylase, such as cancer.

N-monoacylated o-phenylenediamines

The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Styrylsulfonamides

A method for the simultaneous determination of cell proliferation inhibition activity and cell toxicity (induction of cell death) of a substance using a proliferating mammalian cell sample as a test system.

Simultaneous determination of cell proliferation inhibition activity and toxicity

The present invention relates to compounds of formula I, their pharmaceutically acceptable salts as well as their enantiomeric forms, diastereoisomers and racemates; the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds as inhibitors of histone deacetylase (HDAC) and therefore in the control or prevention of illnesses and disorders as mentioned above, or in the manufacture of corresponding pharmaceutical compositions.

Oxime derivatives and their use as pharmaceutically active agents

The present invention describes compounds of the general formula I as well as processes for their manufacture, pharmaceutical compositions containing them and methods for using these compounds and pharmaceutical compositions as pharmaceutical agents. The compounds according to this invention show antiproliferative and differentiation-inducing activity, which results in inhibition of tumor cell proliferation, induction of apoptosis and inhibition of invasion.

Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives

Mono-acylated o-phenylendiamines derivatives of formula A wherein Ar, R, and Rare as described herein, have been found useful for the treatment of diseases mediated by the inhibition of histone deacetylase, such as cancer.

Antibody binding to the SEMP1 antigen and characterized in that said antibody binds to SEMP1 in a manner equivalent to an antibody selected from the group of antibodies DSM ACC2458, DSM ACC2459, DSM ACC2461, and DSM ACC2463 is useful for cancer diagnosis and therapy.

Growing community of inventors

Penzberg, Germany

Manfred Kubbies